About Cingulate Inc.
https://www.cingulate.comCingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders.
CEO
Shane J. Schaffer
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:500K
Value:$45K
HUDSON BAY CAPITAL MANAGEMENT LP
Shares:210.8K
Value:$18.97K
VIRTU FINANCIAL LLC
Shares:10.6K
Value:$954.36
Summary
Showing Top 3 of 6
About Cingulate Inc.
https://www.cingulate.comCingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $5.89M ▲ | $-7.34M ▼ | 0% | $-1.35 ▼ | $-7.23M ▼ |
| Q2-2025 | $0 | $4.5M ▲ | $-4.79M ▼ | 0% | $-1.09 ▼ | $-4.64M ▼ |
| Q1-2025 | $0 | $3.54M ▼ | $-3.8M ▲ | 0% | $-1.04 ▲ | $-3.64M ▲ |
| Q4-2024 | $0 | $6.05M ▲ | $-6.13M ▼ | 0% | $-1.8 ▲ | $-5.97M ▼ |
| Q3-2024 | $0 | $3.12M | $-4.13M | 0% | $-1.83 | $-3.96M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.12M ▼ | $10.52M ▼ | $7.05M ▼ | $3.47M ▼ |
| Q2-2025 | $8.9M ▼ | $13.47M ▲ | $7.96M ▲ | $5.51M ▼ |
| Q1-2025 | $9.52M ▼ | $12.47M ▼ | $6.54M ▼ | $5.93M ▼ |
| Q4-2024 | $12.21M ▲ | $14.86M ▲ | $7.41M ▲ | $7.46M ▼ |
| Q3-2024 | $10.04M | $13.58M | $1.54M | $12.04M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.34M ▼ | $-4.24M ▲ | $0 ▲ | $1.46M ▼ | $-2.78M ▼ | $-4.24M ▲ |
| Q2-2025 | $-4.79M ▼ | $-4.8M ▼ | $-5.92K ▼ | $4.18M ▲ | $-618.78K ▲ | $-4.8M ▼ |
| Q1-2025 | $-3.8M ▲ | $-4.61M ▼ | $0 ▲ | $1.92M ▼ | $-2.69M ▼ | $-4.61M ▼ |
| Q4-2024 | $-6.13M ▼ | $-4.08M ▼ | $-198.46K ▼ | $6.45M ▼ | $2.17M ▼ | $-4.28M ▼ |
| Q3-2024 | $-3.23M | $-3.88M | $140.79K | $13.4M | $9.66M | $-3.74M |
CEO
Shane J. Schaffer
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : B-
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:500K
Value:$45K
HUDSON BAY CAPITAL MANAGEMENT LP
Shares:210.8K
Value:$18.97K
VIRTU FINANCIAL LLC
Shares:10.6K
Value:$954.36
Summary
Showing Top 3 of 6